Australia's Bioxyne jumps on unit securing manufacturing license for medical cannabis
** Shares of Bioxyne BXN.AX rise as much as 75% to
A$0.021, biggest gain since Aug. 20, 2020
** Health and wellness products co says its unit has been
awarded GMP manufacturing license for medical cannabis
** Stock at its highest since July 11
** About 40.2 mln shares change hands, compared with the
30-day average volume of 4.5 mln
** Stock fell 54.2% last year
(Reporting by Neha Soni in Bengaluru)
((Neha.Soni@thomsonreuters.com))
Recent news on BLS Pharmaceuticals
See all newsBrief: Bioxyne Secures A$50M Exclusive German Supply Agreement With Adrex
Australia's Bioxyne rises to near 8-year high after company secures German supply deal
Australia's Bioxyne at two-week high on supply deal with Remidose LATAM
Brief: Bioxyne Expands LATAM Footprint First Supply Agreement Costa Rica
Australia's Bioxyne hits nearly 8-year high on cannabis firm deal